The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.
Simona Soverini
No relevant relationships to disclose
Alessandra Gnani
No relevant relationships to disclose
Caterina De Benedittis
No relevant relationships to disclose
Ilaria Iacobucci
No relevant relationships to disclose
Claudia Venturi
No relevant relationships to disclose
Cristina Papayannidis
No relevant relationships to disclose
Mario Luppi
No relevant relationships to disclose
Serena Merante
No relevant relationships to disclose
Michele Malagola
No relevant relationships to disclose
Domenico Russo
No relevant relationships to disclose
Mario Tiribelli
No relevant relationships to disclose
Marzia Salvucci
No relevant relationships to disclose
Antonella Vitale
No relevant relationships to disclose
Loredana Elia
No relevant relationships to disclose
Marco Vignetti
No relevant relationships to disclose
Robin FoĆ 
No relevant relationships to disclose
Michele Baccarani
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Novartis
Giovanni Martinelli
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis
Honoraria - Bristol-Myers Squibb; Novartis